Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Canevari

Showing results (51-60 of 131) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|June 1, 2001
Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell lineV Appierto, E Cavadini, R Pergolizzi, et al.
Gynecologic Oncology|February 15, 2003
A step further in understanding the biology of the folate receptor in ovarian carcinomaM Bagnoli, S Canevari, M Figini, et al.
Tumori|February 28, 1979
Antibody binding to membrane of cultured melanoma cells by sera of melanoma patientsS Canevari, G Fossati, P Vezzoni, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Anti-idiotypic response to antigrowth factor receptor monoclonal antibodiesE Tosi, O Valota, S Canevari, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1992
Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering moleculesS Ferrini, A Cambiaggi, C Cantoni, et al.
Journal of Cellular Biochemistry|May 1, 1995
Unidirectional potentiation of binding between two anti-FBP MAbs: evaluation of the involved mechanismsP Casalini, D Mezzanzanica, O Valota, et al.
Cancer Research|February 1, 1985
Biochemical analysis of human ovarian cancer-associated antigens defined by murine monoclonal antibodiesS Miotti, S Aguanno, S Canevari, et al.
Cancer Immunology, Immunotherapy : CII|August 18, 2000
Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1M E Perico, D Mezzanzanica, E Luison, et al.
Cancer Detection and Prevention|January 1, 1993
Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cellsS Ferrini, A Cambiaggi, S Sforzini, et al.
International Journal of Cancer|November 15, 1987
Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancerF Leoni, R C Bast, S Canevari, et al.
Pageof 14

Showing results (51-60 of 131) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|June 1, 2001
Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell lineV Appierto, E Cavadini, R Pergolizzi, et al.
Gynecologic Oncology|February 15, 2003
A step further in understanding the biology of the folate receptor in ovarian carcinomaM Bagnoli, S Canevari, M Figini, et al.
Tumori|February 28, 1979
Antibody binding to membrane of cultured melanoma cells by sera of melanoma patientsS Canevari, G Fossati, P Vezzoni, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Anti-idiotypic response to antigrowth factor receptor monoclonal antibodiesE Tosi, O Valota, S Canevari, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1992
Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering moleculesS Ferrini, A Cambiaggi, C Cantoni, et al.
Journal of Cellular Biochemistry|May 1, 1995
Unidirectional potentiation of binding between two anti-FBP MAbs: evaluation of the involved mechanismsP Casalini, D Mezzanzanica, O Valota, et al.
Cancer Research|February 1, 1985
Biochemical analysis of human ovarian cancer-associated antigens defined by murine monoclonal antibodiesS Miotti, S Aguanno, S Canevari, et al.
Cancer Immunology, Immunotherapy : CII|August 18, 2000
Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1M E Perico, D Mezzanzanica, E Luison, et al.
Cancer Detection and Prevention|January 1, 1993
Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cellsS Ferrini, A Cambiaggi, S Sforzini, et al.
International Journal of Cancer|November 15, 1987
Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancerF Leoni, R C Bast, S Canevari, et al.
Pageof 14